EDVA — Endovia Health Sciences Share Price
Last trade - 00:00- $1.63m
- $7.77m
- $0.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 385.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -328559.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11.32 | 18.09 | 18.85 | 0.8 | 0.07 | 17.89 | n/a | -52.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Endovia Health Sciences, Inc., formerly Splash Beverage Group, Inc. seeks to identify, acquire, and build early stage or under-valued beverage brands that have growth potential within its distribution system. The Company’s distribution system is comprehensive in the United States and is expanding to select international markets. Through its division Qplash, Splash’s distribution reach includes e-commerce access to both business-to-business (B2B) and business-to-consumer (B2C) customers. It markets beverage brands to customers throughout the United States that prefer delivery direct to their office, facilities, or homes. Its segments include Splash Beverage Group and E-Commerce. The Company's Splash Beverage Group segment includes the manufacture and distribution of non-alcoholic and alcoholic branded beverages. The E-commerce segment is engaged in the sale of e-commerce beverages. Its brands include Copa di Vino single-serve wine, Pulpoloco Sangria, SALT Tequila, and Chispo Tequila.
Directors
- Robert Nistico CHM (54)
- Dean Huge CFO (61)
- Justin Yorke SEC (55)
- Candace Crawford DRC
- Peter McDonough DRC (62)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- November 5th, 2021
- Public Since
- July 6th, 2018
- No. of Shareholders
- 280
- No. of Employees
- 1
- Sector
- Beverages
- Industry
- Consumer Defensives
- Exchange
- NYSE MKT
- Shares in Issue
- 11,079,337
- Address
- 1314 East Las Olas Blvd, Suite 221 Fort, LAUDERDALE LAKES, 33301
- Web
- https://splashbeveragegroup.com
- Phone
- +1 9415548381
- Auditors
- Rose, Snyder & Jacobs
Latest News for EDVA
Upcoming Events for EDVA
Endovia Health Sciences, Inc. Annual Shareholders Meeting
Q3 2026 Endovia Health Sciences, Inc. Earnings Release
Endovia Health Sciences, Inc. Annual Shareholders Meeting (Dzongkha)
Similar to EDVA
Reed'S
NYSE MKT
FAQ
As of Today at 02:28 UTC, shares in Endovia Health Sciences are trading at $0.15. This share price information is delayed by 15 minutes.
Shares in Endovia Health Sciences last closed at $0.15 and the price had moved by -98.32% over the past 365 days. In terms of relative price strength the Endovia Health Sciences share price has underperformed the S&P500 Index by -98.56% over the past year.
The overall consensus recommendation for Endovia Health Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEndovia Health Sciences does not currently pay a dividend.
Endovia Health Sciences does not currently pay a dividend.
Endovia Health Sciences does not currently pay a dividend.
To buy shares in Endovia Health Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.15, shares in Endovia Health Sciences had a market capitalisation of $1.63m.
Here are the trading details for Endovia Health Sciences:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: EDVA
Based on an overall assessment of its quality, value and momentum Endovia Health Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Endovia Health Sciences is $40.00. That is 27110.88% above the last closing price of $0.15.
Analysts covering Endovia Health Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$13.20 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Endovia Health Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -90.52%.
As of the last closing price of $0.15, shares in Endovia Health Sciences were trading -88.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Endovia Health Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Endovia Health Sciences' management team is headed by:
- Robert Nistico - CHM
- Dean Huge - CFO
- Justin Yorke - SEC
- Candace Crawford - DRC
- Peter McDonough - DRC